Rodeo Therapeutics is a preclinical-stage biopharmaceutical company. It is focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.
|HQ||Seattle, WA, US||Map|
Rodeo Therapeutics total Funding
Rodeo Therapeutics latest funding size
Time since last funding
|3 years ago|
Rodeo Therapeutics investors
|WRF Capital, ARCH Venture Partners, Eli Lilly, WuXi AppTec, Johnson & Johnson Innovation, AbbVie Biotech Ventures, Watson Fund, Accelerator Corporation, Alexandria Venture Investments|
Who are Rodeo Therapeutics key executives?
Rodeo Therapeutics's key executives are Sanford Markowitz, Joseph Ready and Stanton Gerson.
Who are Rodeo Therapeutics competitors?
Competitors of Rodeo Therapeutics include Finnadvance, Pharmacology Research Institute and DendroPharm.
Where is Rodeo Therapeutics headquarters?
Rodeo Therapeutics headquarters is located at 2815 Eastlake Ave E #300, Seattle.
Where are Rodeo Therapeutics offices?
Rodeo Therapeutics has an office in Seattle.
How many offices does Rodeo Therapeutics have?
Rodeo Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies